Article ; Online: CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.
PloS one
2019 Volume 14, Issue 5, Page(s) e0217091
Abstract: ... to prevent tuberculosis. This study examined whether DAR-901 (a) induces CD4+ T cell cytokine profiles ... signature compared to BCG or placebo.: Methods: We analysed CD4+ T cell cytokine immune responses from 10 ... placebo followed by an intradermal injection of BCG. Antigen-specific functional and phenotypic CD4+ T ...
Abstract | Background: DAR-901 is an inactivated whole cell tuberculosis booster vaccine, prepared using a new scalable, broth-grown method from the master cell bank of SRL172, a vaccine previously shown to prevent tuberculosis. This study examined whether DAR-901 (a) induces CD4+ T cell cytokine profiles previously proposed as correlates of protection and (b) has a specific vaccine-induced immunological signature compared to BCG or placebo. Methods: We analysed CD4+ T cell cytokine immune responses from 10 DAR-901 recipients, 9 BCG recipients and 9 placebo recipients from the Phase I DAR-901 MDES trial. In that study, HIV-negative, IGRA-negative participants with prior BCG immunization were randomized (double-blind) to receive three intradermal injections of DAR-901 or saline placebo or two injections of saline placebo followed by an intradermal injection of BCG. Antigen-specific functional and phenotypic CD4+ T cell responses along with effector phenotype of responder cells were measured by intracellular cytokine staining. Results: DAR-901 recipients exhibited increased DAR-901 antigen-specific polyfunctional or bifunctional T cell responses compared to baseline. Vaccine specific CD4+ IFNγ, IL2, TNFα and any cytokine responses peaked at 7 days post-dose 3. Th1 responses predominated, with most responder cells exhibiting a polyfunctional effector memory phenotype. BCG induced greater CD4+ T cell responses than placebo while the more modest DAR-901 responses did not differ from placebo. Neither DAR-901 nor BCG induced substantial or sustained Th17 /Th22 cytokine responses. Conclusion: DAR-901, a TB booster vaccine grown from the master cell bank of SRL 172 which was shown to prevent TB, induced low magnitude polyfunctional effector memory CD4+ T cell responses. DAR-901 responses were lower than those induced by BCG, a vaccine that has been shown ineffective as a booster to prevent tuberculosis disease. These results suggest that induction of higher levels of CD4+ cytokine stimulation may not be a critical or pre-requisite characteristic for candidate TB vaccine boosters. Trial registration: ClinicalTrials.gov NCT02063555. |
---|---|
MeSH term(s) | Adolescent ; Adult ; Aged ; BCG Vaccine/administration & dosage ; BCG Vaccine/immunology ; CD4-Positive T-Lymphocytes/immunology ; Cytokines/metabolism ; Double-Blind Method ; Female ; Humans ; Immunization, Secondary ; Male ; Middle Aged ; Mycobacterium tuberculosis/immunology ; Mycobacterium tuberculosis/pathogenicity ; Tuberculosis/immunology ; Tuberculosis/metabolism ; Tuberculosis/prevention & control ; Tuberculosis Vaccines/administration & dosage ; Tuberculosis Vaccines/immunology ; Tuberculosis Vaccines/standards ; Young Adult |
Chemical Substances | BCG Vaccine ; Cytokines ; Tuberculosis Vaccines |
Language | English |
Publishing date | 2019-05-23 |
Publishing country | United States |
Document type | Clinical Trial, Phase I ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't |
ISSN | 1932-6203 |
ISSN (online) | 1932-6203 |
DOI | 10.1371/journal.pone.0217091 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.